2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - New Orleans Theatre A
Technology and Procedures, Assays, Imaging, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

397 Losing a brake creates a target: TOX is a tumor suppressor whose loss confers NF-κB addiction in ABC-DLBCL

Khouloud Kouidri, MD, Eloisi Caldas Lopes, PhD2, Rossella Marullo, MD, PhD3, Maria Victoria Revuelta, PhD4, Federico Nahuel Ruiz Moreno, PhD5, Matthew Teater, PhD6, Subhashini Joshi, PhD7, Nahuel Zamponi, PhD8, Ari Melnick, MD9, Giorgio Inghirami, MD10, Leandro Cerchietti, MD11
1 NYU Langone Health, New York City, United States
2 Josep Carreras Leukaemia Research Institute, Barcelona, Spain
3 Weill Cornell Medicine, New York, New York, United States
4 NYU Langone Health, New York City, United States
5 NYU Langone Health, New York City, United States
6 NYU Langone Health, New York City, United States
7 NYU Langone Health, New York City, United States
8 NYU Langone Health, New York City, United States
9 Josep Carreras Leukaemia Research Institute, Barcelona, Spain
10 Weill Cornell Medicine, New York, New York, United States
11 NYU Langone Health, New York City, United States
The MCD/C5 subtype of activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is defined by co-occurring CD79B and MYD88L265P mutations and driven by constitutive NF-κB activation. Heterozygous or homozygous (rare) TOX loss occurs in ~50% of MCD/C5 DLBCL, suggesting a tumor-suppressor role. Paradoxically, in germinal-center (GC) B cells, TOX is induced alongside NF-κB-driven plasmacytic differentiation, positioning it as a molecular rheostat that tunes NF-κB activity. We therefore investigated whether TOX restrains NF-κB and whether its loss creates a therapeutic vulnerability in poor-prognosis ABC-DLBCL.
Across +4,600 DLBCL transcriptomes, TOX expression was lower in ABC-like DLBCL (p<0.001), and progressively lower TOX quantiles predicted worse overall survival (p=3×10??), consistent with a putative tumor-suppressor role. To test this notion, we generated an isogenic TOX-knockout MCD-DLBCL line (TMD8) by CRISPR. TOX-deficient cells showed increased proliferation, resistance to multiple chemotherapies, and heightened NF-κB, STAT3, and TNF-α pathway activity. They also secreted, in a NF-κB-dependent manner, more IL6 and IL10, key immunosuppressive cytokines in the lymphoma microenvironment (LME). Mirroring this, the LME of patients with lower TOX expression had a higher proportion of immunosuppressed cells and levels of IL6 and IL10, linking tumor-intrinsic NF-κB hyperactivation to a pro-tumoral LME. 
To mechanistically establish these associations, we generated Cγ1-Cre conditional heterozygous and homozygous TOX deletion models on an MCD-like background (CD79B-Y196H; MYD88-L252P; BCL2) and performed adoptive-transfer lymphomagenesis. Across the six genotypes (MCD, MCD-TOX-HET, MCD-TOX-HOM, TOX-HET, TOX-HOM, Cγ1-Cre; n=25 per cohort), MCD-TOX-HET mice had the most aggressive disease, with a median overall survival of 248 days versus 301 days for MCD and not reached in all other cohorts (p<0.0001). MCD-TOX-HOM mice did not differ significantly from MCD, suggesting a compensatory mechanism at complete loss. The splenic LME of MCD-TOX-HET mice showed CD8+ T-cell dysfunction and immunosuppression, recapitulating the human LME features.
We next asked whether in the context of MCD/C5 DLBCL, TOX loss constitutes an actionable dependency. In a cell viability screen of 20 compounds targeting distinct NF-κB pathway components and upstream regulators, the BTK inhibitor acalabrutinib and the MALT1 inhibitor JNJ-67690246 were 2-3-fold more active against TOX deficient than isogenic parent TMD8 cells. In vivo, in TMD8 xenografts (TOX-deficient vs. TOX-WT, n=10 per condition), both agents preferentially reduced tumor burden in TOX-deficient tumors (acalabrutinib, vehicle vs. treated p=0.0008; JNJ-67690246, vehicle vs. treated p=0.0174), with no significant activity (vs. vehicle) observed in TOX-wildtype tumors, confirming unrestrained NF-κB hyperactivation as a specific, targetable vulnerability of TOX deficient MCD/C5 DLBCL.
Using orthogonal human and murine approaches, we establish TOX as a bona fide tumor-suppressor in ABC-DLBCL whose loss drives NF-κB-dependent tumor-intrinsic aggression and a pro-tumoral, immunosuppressive LME. The preferential sensitivity of TOX-deficient lymphoma to BTK and MALT1 inhibition nominates TOX loss-of-function as an actionable biomarker for therapeutic stratification of high-risk MCD/C5 DLBCL patients.
Khouloud Kouidri, MD: No relevant conflicts of interest to declare.